The study, reported by Medical Express, involved 406 patients with type 2 diabetes and excess weight. Participants received either electrolyprone at various doses or a placebo. The effectiveness of the therapy was assessed after 26 weeks of treatment.
Elecoglipron is a glucagon-like peptide-1 receptor agonist. Most drugs in this class are currently administered subcutaneously. Elecoglipron was developed as a more convenient oral alternative for the direct treatment of diabetes. It is taken once daily without any associated restrictions.
The results showed that nearly 90% of patients achieved glycated hemoglobin levels—a standard indicator of disease control—of no more than 7%. In the placebo group, approximately 25% of participants achieved this result. The drug also promoted weight loss. Approximately 72% of participants lost at least 5% of their body weight, compared to only 20% of those in the placebo group.
"Until now, AGLP-1 drugs have primarily been available as injectables or peptide tablets, which has limited their use. Elecoglipron could expand treatment options without compromising efficacy," the scientists concluded.
Previously, clinical trials explored the potential of gene therapy for diabetes treatment for the first time. Scientists hope that a single dose of therapy could replace years of AGLP-1-based medications and provide long-term blood sugar control.
